Foresight Group LLP has announced a £1.25m growth capital investment into Fertility Focus Limited (FFL), a fertility monitoring technology company that has developed OvuSense, a registered medical device that enables women to predict ovulation.
The investment was led by Foresight on behalf of Foresight VCT plc and Foresight 4 VCT plc as part of a larger £2m funding round, supported by new and existing investors including private high net-worth individuals.
Based in Warwick, FFL was established in 2005 to commercialise the intellectual property developed by a team from Bristol University that identified the ability to determine and predict ovulation with a high degree of accuracy by monitoring subtle changes in body temperature.
Leveraging this knowledge, FFL developed OvuSense, a sensor that monitors core body temperature. When combined with the proprietary algorithm available on the company’s smartphone app, OvuSense is able to predict ovulation up to 24 hours in advance in real time and detect ovulation in advance with 99% accuracy.
OvuSense remains highly effective in women with irregular cycles and who suffer from ovulatory conditions such as Polycystic Ovarian Syndrome and as such the technology is specifically targeted at the over 4 million women who have difficulty conceiving.
FFL’s management team is led by CEO Robert Milnes – an expert in his field with more than 29 years’ experience in medical devices, with 20 years focused on women’s health – and non-exec chairman Steve Godber, ex Vickers Medical and Forum Bioscience.
20 scaleups join Tech Nation’s cyber security growth programme
Foresight’s investment will primarily be used to invest in sales and marketing and will also fund a clinical trial to further prove the benefits of OvuSense as a tool to diagnose ovulatory issues.
Rob Jones, investment manager, Foresight Group, said: “We have been impressed by the rapid progress FFL has made since launch of the second-generation OvuSense product with strong sales traction in the US and UK.
“FFL is a well-run business that has developed an innovative, clinically supported and IP rich product in OvuSense. We are looking forward to working alongside Rob Milnes and the wider management team on the next stage of the company’s growth.”
Rob Milnes, CEO, OvuSense, commented: “We are thrilled to be working with Foresight to grow our team and accelerate our sales and marketing activity. The investment marks an important stage in our development. With Foresight’s deep experience and support, FFL is well prepared and equipped for further growth.”